Great commentary all. Much appreciated.
It seems the market is wanting to see revenue figures or at least potential. There is plenty of tech out there that looks very interesting and beneficial, but ultimately marketing and brand building determine the success. We ultimately need to trust Craig is the right person for that. I know I much prefer a marketing man at the helm than an academic.
It terms of MedTech, we are in the biggest potential market (most deaths and most suffers both stems from a lack of cardiovascular health). So we are in the right sector. The tech is also clinically validated and already used by pharma's to get the most accurate heart data. So it's efficacious. Now it comes down to showing the 'value add' to clinicians, doctors and consumers. Ultimately, how will the Pulse make my patients/me less at risk of dying/feel better?
I anticipate they have been using their time since CES to build partnerships. And I wouldn't be surprised if we will hear about one of them very soon. Considering all this hiring, it makes sense (although isn't a foregone conclusion). I imagine a lot of partnerships were awaiting FDA approval. Hopefully, we hear about them before the Nasdaq raise.
Add to My Watchlist
What is My Watchlist?
